Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$3.11
$3.22
$1.98
$3.60
$29.23M1.5222,722 shs12,261 shs
Imunon, Inc. stock logo
CLSN
Imunon
$2.22
$1.80
$15.75
$13.91M2.27150,471 shs711 shs
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
$4.34
$4.34
$1.40
$4.58
$37.54M0.7497,474 shsN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$1.07
-1.8%
$0.98
$0.78
$5.15
$37.25M1.57442,850 shs265,579 shs
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$0.40
$0.10
$6.74
$423.91M0.772.19 million shs161,505 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
0.00%0.00%0.00%0.00%+2.30%
Imunon, Inc. stock logo
CLSN
Imunon
0.00%0.00%0.00%0.00%0.00%
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
0.00%0.00%0.00%0.00%+181.82%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-1.83%-10.08%+12.63%+3.88%-48.56%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/AN/AN/AN/A
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.8761 of 5 stars
3.73.00.04.12.20.80.0
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$10.00221.54% Upside
Imunon, Inc. stock logo
CLSN
Imunon
0.00
N/AN/AN/A
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
3.00
Buy$8.6398.73% Upside
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.33
Buy$4.00273.83% Upside
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$6.57 per shareN/A
Imunon, Inc. stock logo
CLSN
Imunon
$500K0.00N/AN/A$9.66 per share0.00
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
$2.21M17.02N/AN/A$3.45 per share1.26
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$101.49M0.36$0.12 per share8.62$1.01 per share1.06
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$660K0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/A
Imunon, Inc. stock logo
CLSN
Imunon
-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/A
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
-$34.03M-$4.29N/AN/AN/A-1,583.49%-233.03%-129.88%N/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$480KN/A0.00N/AN/A-0.27%-0.90%-0.47%8/14/2025 (Estimated)
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/A

Latest CLSN, LUMO, ACST, RMTI, and VBLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/A
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
N/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
7.86
7.86
Imunon, Inc. stock logo
CLSN
Imunon
0.13
6.52
6.52
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/A
2.66
2.66
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.30
2.95
2.50
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/A
4.63
4.63

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
Imunon, Inc. stock logo
CLSN
Imunon
12.97%
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
33.99%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23.31%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.96%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
Imunon, Inc. stock logo
CLSN
Imunon
4.66%
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
25.40%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.60%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
6.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.77 millionNot Optionable
Imunon, Inc. stock logo
CLSN
Imunon
277.10 million6.77 millionOptionable
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
308.65 million6.45 millionNot Optionable
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
30034.17 million32.95 millionOptionable
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
777.64 million72.88 millionOptionable

Recent News About These Companies

AlboGraft Polyester Vascular Graft from LeMaitre
Tommy Garten elected to VBL Hall of Fame
Vascular News and Research
Notable Labs Closes Merger Transaction With VBL Therapeutics
Vascular Biogenics Rises on Presentation Hype

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acasti Pharma stock logo

Acasti Pharma NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Imunon stock logo

Imunon NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Lumos Pharma stock logo

Lumos Pharma NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Rockwell Medical stock logo

Rockwell Medical NASDAQ:RMTI

$1.07 -0.02 (-1.83%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.03 (+3.18%)
As of 07/16/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Vascular Biogenics stock logo

Vascular Biogenics NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.